Search
Verona Pharma PLC
VRNAAdd to Watchlist
106.910USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
73.55BMarket Cap
LossP/E TTM
More Details of Verona Pharma PLC Company
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLC Info
Ticker SymbolVRNA
Company nameVerona Pharma PLC
IPO dateMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Number of employees209
Security typeDepository Receipt
Fiscal year-endMar 30
AddressRiverside
CityLONDON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited Kingdom
Postal codeSE1 2RE
Phone442032834200
Websitehttps://www.veronapharma.com/
Ticker SymbolVRNA
IPO dateMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Company Executives of Verona Pharma PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
FAQs
Who are the top five shareholders of Verona Pharma PLC?
The top five shareholders of Verona Pharma PLC are: Mr. Andrew Fisher
How many institutions hold shares of Verona Pharma PLC (VRNA)?
As of 2025Q3, 467 institutions hold shares of Verona Pharma PLC, with a combined market value of approximately 76.61M, accounting for 88.88% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7116945.00.
